BioArctic AB (publ)

DB:B9A Stock Report

Market Cap: €1.6b

BioArctic Management

Management criteria checks 3/4

BioArctic's CEO is Gunilla Osswald, appointed in Jan 2014, has a tenure of 10.92 years. total yearly compensation is SEK22.38M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €1.75M. The average tenure of the management team and the board of directors is 5.9 years and 6.9 years respectively.

Key information

Gunilla Osswald

Chief executive officer

SEK 22.4m

Total compensation

CEO salary percentage19.8%
CEO tenure10.9yrs
CEO ownership0.1%
Management average tenure5.9yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gunilla Osswald's remuneration changed compared to BioArctic's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 233m

Jun 30 2024n/an/a

-SEK 88m

Mar 31 2024n/an/a

-SEK 122m

Dec 31 2023SEK 22mSEK 4m

SEK 229m

Sep 30 2023n/an/a

SEK 259m

Jun 30 2023n/an/a

SEK 270m

Mar 31 2023n/an/a

SEK 327m

Dec 31 2022SEK 9mSEK 5m

-SEK 11m

Sep 30 2022n/an/a

SEK 28m

Jun 30 2022n/an/a

-SEK 147m

Mar 31 2022n/an/a

-SEK 135m

Dec 31 2021SEK 5mSEK 3m

-SEK 120m

Sep 30 2021n/an/a

-SEK 114m

Jun 30 2021n/an/a

-SEK 97m

Mar 31 2021n/an/a

-SEK 101m

Dec 31 2020SEK 5mSEK 3m

-SEK 69m

Sep 30 2020n/an/a

-SEK 72m

Jun 30 2020n/an/a

-SEK 60m

Mar 31 2020n/an/a

SEK 78m

Dec 31 2019SEK 7mSEK 3m

SEK 88m

Sep 30 2019n/an/a

SEK 441m

Jun 30 2019n/an/a

SEK 475m

Mar 31 2019n/an/a

SEK 380m

Dec 31 2018SEK 5mSEK 3m

SEK 382m

Sep 30 2018n/an/a

SEK 58m

Jun 30 2018n/an/a

SEK 32m

Mar 31 2018n/an/a

SEK 29m

Dec 31 2017SEK 3mSEK 2m

SEK 15m

Compensation vs Market: Gunilla's total compensation ($USD2.03M) is about average for companies of similar size in the German market ($USD1.58M).

Compensation vs Earnings: Gunilla's compensation has increased whilst the company is unprofitable.

CEO

Gunilla Osswald (63 yo)

10.9yrs

Tenure

SEK 22,378,000

Compensation

Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...

Leadership Team

NamePositionTenureCompensationOwnership
Gunilla Osswald
President & CEO10.9yrsSEK 22.38m0.11%
€ 1.7m
Pär Gellerfors
Co-Founder21.9yrsSEK 390.00kno data
Lars Lannfelt
Co-Founder21.9yrsSEK 2.54m33.41%
€ 546.1m
Anders Martin-Lof
Chief Financial Officer1.6yrsno datano data
Johanna Fälting
Chief Research Officer & Head of Researchno datano data0.051%
€ 829.7k
Christer Möller
VP of Pre-Clinical Development & Chief Scientific Officer18.9yrsno data0.063%
€ 1.0m
Oskar Bosson
VP and Head of IR & Communication4.6yrsno data0.016%
€ 264.5k
Leif Gallo
General Counsel and Head of Legal & IPno datano datano data
Harald Borgeke
Head of Public Affairs2.7yrsno datano data
Frida Lekander
Head of Marketing2.8yrsno datano data
Gunilla Andersson
Vice President of Human Resources5.9yrsno datano data
Mikael Moge
VP & Head of CMCno datano data0.011%
€ 172.4k

5.9yrs

Average Tenure

63yo

Average Age

Experienced Management: B9A's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Pär Gellerfors
Co-Founder21.9yrsSEK 390.00kno data
Lars Lannfelt
Co-Founder21.9yrsSEK 2.54m33.41%
€ 546.1m
Eugen Steiner
Independent Chairman7.3yrsSEK 621.00k0.10%
€ 1.6m
Hans Wigzell
Member of Scientific Advisory Boardno datano datano data
Konrad Beyreuther
Member of the Scientific Boardno datano datano data
Marie Edström
Independent Director1.5yrsSEK 187.00kno data
Mikael Smedeby
Independent Director6.6yrsSEK 316.00k0.032%
€ 527.8k
Charlotta Ljungqvist
Independent Director3.6yrsSEK 318.00k0.0036%
€ 58.4k
Martin Ingelsson
Member of Scientific Boardno datano datano data
Staffan Pauli
Member of Scientific Advisory Boardno datano datano data
Ken Marek
Member of Scientific Advisory Boardno datano datano data
Kaj Blennow
Member of Scientific Advisory Boardno datano datano data

6.9yrs

Average Tenure

70yo

Average Age

Experienced Board: B9A's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioArctic AB (publ) is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Patrik LingDNB Markets
Rajan SharmaGoldman Sachs